Biogen shares soared on reports the company has drawn takeover interest from rival companies, the Wall Street Journal said.
Sources say Allergan is unlikely to pursue Biogen deal. CNBC's Meg Tirrell reports the details. The "Fast Money" traders weigh in.
The Fast Monet Trader's discuss the surge in Biogen after talk of a possible buyout.
CNBC's Bob Pisani looks at the day's market action.
CNBC's Meg Tirrell discusses Biogen drawing interest from Merck and Allergan, as possible acquisition, according to Dow Jones.
Biogen gets interest from Merck and Allergan, according to Dow Jones.
The "Fast Money" traders share their first moves for the market open.
Jim Cramer provided his long-term view of the market, as the notoriously difficult month of August begins.
Jim Cramer spoke with the CEO of Ionis Pharmaceuticals, which skyrocketed on Monday following positive data its SMA drug.
The "Fast Money" traders share their final trades of the day, including J.C. Penney, Biogen and more.
Biogen and Ionis Pharmaceuticals shares soared after an analysis showed a drug for a deadly muscle disorder in infants met its main goal.
Biogen and Ionis Pharmaceuticals soar on a new muscle-disorder drug for babies, CNBC's Meg Tirrell reports. The "Fast Money Halftime Report" traders weigh in.
Jim Cramer explains what to watch ahead of the open including Ionis Pharmaceuticals and Biogen.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
U.S. stocks closed lower as oil prices weighed and the market consolidated ahead of next week's Fed meeting.
CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm.
Big drug discoveries have been scant, but investors can find long-term value in some biotech names, said Mark Schoenebaum of Evercore ISI.
Mark Schoenebaum, Evercore ISI analyst, discusses his thoughts on the biotech rally.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at five stocks with analyst recommendations, including UBS calling for shorting opportunities for CBS Corp and Morgan Stanley downgrading Chipotle.
CNBC's Meg Tirrell discusses biotech in the bear market and what to expect going forward.